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Abstract
Background Chemotherapy-induced neutropenia (CIN)
places patients at risk of life-threatening infections. While
reduction of chemotherapy dose or delay of the subsequent
treatment cycle and, consequently, reduction of relative
dose intensity (RDI) may limit myelotoxicity, these actions
can also impact adversely on treatment outcome and should
be avoided in adjuvant settings.
Patients and methods Based on data from 444 breast cancer
patients in the INC-EU Prospective Observational European
Neutropenia Study, we have evaluated patient-specific and
treatment-specific factors that impact on the incidence of
grade 4 CIN (absolute neutrophil count <0.5×109/L), either
during the first or in any cycle of (neo)adjuvant chemo-
therapy, across a range of regimens and doses.
Results Using multivariate logistic regression analysis, risk
factors for grade 4 CIN were identified as older age, lower
weight, higher planned dose intensity of doxorubicin,
epirubicin, or docetaxel, higher number of planned cycles,
vascular comorbidity, lower baseline white blood cell
count, and higher baseline bilirubin. Use of colony-
stimulating factor before a neutropenic event occurred,
dose delays, and dose reductions were protective against
grade 4 CIN.
Conclusions By identifying risk factors for grade 4 CIN,
CSF prophylaxis may be appropriately targeted to prevent
low RDI in patients treated with curative intent.
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Introduction
Breast cancer is the most common form of cancer among
women in Europe, with an incidence of 110 per 100,000
and mortality of 25 per 100,000 in 2006 [1]. Disease-free
survival (DFS) and overall survival (OS) rates have
significantly improved in the last 30 years with the
introduction of treatment with adjuvant chemotherapy in
addition to surgery [2]. However, the benefits of adjuvant
chemotherapy are largely dependent on optimal dose
delivery, without dose delays and reductions [3–5]. In a
20-year follow-up study of women treated with cyclophos-
phamide, methotrexate, and 5-fluorouracil (CMF) for node-
positive breast cancer, receiving full-dose chemotherapy
(≥85%) impacted positively on DFS and OS [3]. A more
recent study of anthracycline-based nontaxane chemother-
apy regimens similarly showed benefits in DFS and OS for
patients receiving full-dose and on-schedule chemotherapy
(≥85%) [5]. The benefit of higher dose intensity for DFS and
OS has also been demonstrated for adjuvant 5-fluorouracil,
doxorubicin, and cyclophosphamide (FAC) chemotherapy in
the treatment of node-positive breast cancer [4].
Chemotherapy frequently results in severe chemotherapy-
induced neutropenia (grade 4 CIN; absolute neutrophil count
[ANC] <0.5×109/L) and febrile neutropenia (FN; ANC
<0.5×109/L and temperature ≥38°C). Myelosuppression
puts patients at risk of life-threatening infection. In Europe,
it is common practice in many hospitals to delay or reduce
chemotherapy doses in an effort to minimize this risk or in
response to the occurrence of a myelosuppressive event or
low neutrophil nadir. For example, Chirivella et al. reported
that, in their hospital it was standard protocol to delay
chemotherapy by 5–7 days even at lower grades of
neutropenia, if the neutrophil count was <1.5×109/L or if
the platelet count was <100×109/L [5]. The Neulasta
[pegfilgrastim] versus Current Practice (NeuCuP) integrated
analysis also demonstrated the occurrence of dose delays in
current practice [6]. Consequently, patients receive reduced
relative dose intensity (RDI) [7]. We have previously
reported that the practice of dose delays and reductions
affects a high proportion of breast cancer patients; 34% of
patients in the INC-EU Prospective Observational Europe-
an Neutropenia Study experienced grade 4 CIN, over 20%
received a reduced RDI (≤85%), and grade 4 CIN was a
significant predictor of low RDI, dose delays, and dose
reductions [8].
Colony-stimulating factor (CSF) primary prophylaxis can be
used to support chemotherapy delivery by reducing the
duration of severe neutropenia [9–12]. Current European
Organisation for Research and Treatment of Cancer (EORTC)
guidelines recommend primary prophylaxis for patients where
reductions in dose intensity have been shown to result in
poorer prognosis, even where the overall FN risk is low [10].
The aim of the present analysis was to evaluate factors
that predict grade 4 CIN in early stage breast cancer
patients treated with curative intent, a patient group for
whom delivery of full RDI has been shown to benefit
survival [3–5]. By identifying risk factors, protective
measures may be targeted towards patients most at risk of
developing neutropenia and subsequent chemotherapy dose
delays and reductions.
Materials and methods
Study design and patient selection
The study design and patient selection have previously
been described in detail [8]. Briefly, the INC-EU Prospec-
tive Observational European Neutropenia Study involved
749 patients with histologically confirmed breast cancer,
non-Hodgkin lymphoma, or Hodgkin lymphoma enrolled at
66 centers in Belgium, France, Germany, Spain, and the
UK between January 2004 and May 2005. Ethical approval
was obtained from all participating centers, and all patients
provided informed consent. The present analysis covers a
subset of 444 breast cancer patients. Patients eligible for
inclusion required adjuvant or neoadjuvant chemotherapy
for grade I–III breast cancer, with at least four cycles of a
myelosuppressive chemotherapy regimen sequence planned.
Permitted chemotherapy regimens included anthracycline-
containing regimens including doxorubicin and cyclophos-
phamide (AC), epirubicin and cyclophosphamide (EC),
FAC, 5-fluorouracil, epirubicin, and cyclophosphamide
(FEC), and epirubicin, cyclophosphamide, methotrexate,
and 5-fluorouracil (E-CMF); taxane-containing or sequential
regimens including docetaxel, doxorubicin, and cyclophos-
phamide (TAC); and CMF.
Statistical methods
From an initial set of covariates considered to be potential
predictors of grade 4 CIN (ANC <0.5×109/L), based on
biomedical/clinical reasoning and given earlier published
reports, candidate model covariates were preselected on the
basis of statistical criteria (presence of an association with
p≤0.25 in standard univariate analysis) and clinical
relevance. Subsequently, multivariate logistic regression
models of grade 4 CIN occurrence in any cycle and in
cycle 1 were developed. Main effects were identified
through manual exploration of all plausible combinations
of candidate covariates. Generalized estimation equations-
based robust standard error estimates were used to allow for
clustering by study center. For candidate predictors with
more than 5% missing values, missing categories were
introduced in order to avoid loss of observations. Sensitiv-
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ity analyses were performed to address concerns that this
approach can lead to biased estimation results [13, 14].
Model fit was assessed using the Hosmer–Lemeshow
goodness of fit test and plots of mean observed versus mean
predicted event probabilities, by deciles of the linear
predictor. Predictive ability of the models was characterized
by sensitivity and specificity, positive predictive value and
negative predictive value (PPV and NPV, respectively), the
area under the receiver operating characteristic (ROC)
curve, and the total proportion of correct predictions. The
ability of the models to predict lower grades of CIN ≥3
(ANC <1.0×109/L) or ≥2 (ANC <1.5×109/L) was also
tentatively determined. Tenfold cross-validation was per-
formed in the absence of an independent validation dataset.
Finally, clinical utility of the “any cycle” model was
assessed by applying the model to hypothetical case
scenarios.
The initial set of potential predictors of grade 4 CIN in
any cycle included patient factors, baseline laboratory
measures and comorbidities, frequency of hematology
laboratory tests, planned treatment characteristics, and
actual treatment characteristics before a grade 4 CIN
occurred. For the model of grade 4 CIN occurrence in
cycle 1 of chemotherapy, an appropriate subset of these
covariates was considered.
Results
Patient and treatment characteristics
Patient and baseline disease characteristics are shown inTable 1.
The majority of patients (70%) received anthracycline-based
treatments; the remaining patients received anthracycline-
containing and taxane-containing sequential regimens (20%),
TAC (4%), other taxane-containing regimens (2%), or CMF
(4%). Patients receiving nonsequential chemotherapy regi-
mens were planned for four cycles (25%) or six cycles (72%)
in the vast majority of cases. Patients receiving sequential
regimens were typically planned for six cycles (10%) or eight
cycles (89%). Cycles were 3 weeks long in most cases.
Primary CSF prophylaxis was provided to 9% of patients
overall (5% for anthracycline-based regimens, 14% for
anthracycline-containing and taxane-containing regimens,
71% for TAC, and 11% for CMF), and secondary CSF
prophylaxis or treatment was provided to a further 24% of
patients.
Incidence of CIN
Overall, grade 4 CIN occurred in around a third of patients
(152 out of 442; 34%) at some stage during their treatment
(Table 2) and was most frequent in patients receiving TAC
chemotherapy (seven out of 17; 44%). Over two thirds of
all grade 4 CIN events (107 out of 152; 70%) occurred
during the first cycle of treatment, and almost one in four
breast cancer patients (107 out of 442; 24%) experienced
first cycle grade 4 CIN. Lower grades of CIN were also
frequent. Across all cycles, maximum CIN grades of 3, 2,
and 1 were seen in 132 (30%), 72 (16%), and 67 (15%) of
442 patients, respectively. Only 19 patients (4%) experi-
enced no CIN.
Chemotherapy dose limitations
Patients were more likely to receive a reduced RDI (≤85%)
if they experienced grade 4 CIN whether in the first cycle
of chemotherapy or at any other point during treatment
(Table 3). In patients without grade 4 CIN, the risk of RDI
≤85%was 17% (95% confidence interval [95%CI], 13–22%),
whereas in patients with grade 4 CIN in any cycle, the risk of
RDI ≤85% was 28% (95% CI, 21–36%). The occurrence of
grade 4 CIN in any cycle of chemotherapy was also
significantly associated with dose delays (≥4 days; odds ratio
[OR], 1.57; 95%CI, 1.02–2.40) and dose reductions (≥10% of
planned dose; OR, 1.86; 95% CI, 1.16–2.97).
Table 1 Patient and baseline disease characteristics
Characteristics (N=444)
Age (years), mean ± SD (range) 53.5±10.2 (27–81)
Female gender, n (%) 441 (99.3)
Weight (kg), mean ± SD (range)a 71.5±14.2 (41–138)
BSA (m2), mean ± SD (range) 1.8±0.2 (1.3–2.3)
HER2/Neu status, n (%)b
0 199 (53.1)
1+ 54 (14.4)
2+ 40 (10.7)
3+ 82 (21.9)
Disease stage at inclusion, n (%)c
I 109 (24.9)
II 241 (55.0)
III 88 (20.1)
No. of baseline comorbidities,
mean ± SD (range)
1.6±2.1 (0–11)
Vascular comorbidity, n (%)d 87 (19.6)
Baseline WBC <5×109/L, n (%) 59 (13.4)
Baseline bilirubin >17.1 µmol/L
(1.0 mg/dl), n (%)
17 (4.0)
BSA body surface area, SD standard deviation, WBC white blood cell
count
aN=441 due to missing values
bN=375 due to missing values
cN=438 due to missing values
dMost of these patients had hypertension
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Predictors of CIN
Significant risk factors associated with the occurrence of
grade 4 CIN in any cycle of chemotherapy were identified
using logistic regression analysis (Table 4). These were
older age, lower weight, higher planned dose intensity of
doxorubicin, epirubicin, or docetaxel, higher number of
planned cycles, vascular comorbidity, lower baseline WBC
count, and higher baseline bilirubin. A higher number of
hematology laboratory tests per cycle and availability of a
cycle 1 nadir hematology laboratory test were also shown
to be significant in the model, but this may be related to
patient management and not a direct correlation between
these tests and CIN. The model also identified factors that
protected against grade 4 CIN; these were CSF use, dose
reductions, and dose delays, all before an event occurred.
We investigated whether weight may have been identi-
fied as a predictor of grade 4 CIN because body surface
area (BSA)-based chemotherapy dosing leads to higher
chemotherapy dose per kilogram of body weight in lighter
patients. Consistent with this hypothesis, substantial and
highly significant negative correlations between BSA and
dose per kilogram body weight were found for a wide range
of antimalignant substances. For example, the correlation
between BSA and absolute doxorubicin dose per kilogram
body weight in the first cycle of chemotherapy was −0.76
for TAC (N=88; p<0.001) and −0.81 for AC chemotherapy
(N=17; p<0.001; Fig. 1).
The model correctly classified 320 of 434 patients
(73%). The area under the ROC curve was 0.82 (95% CI,
0.78–0.86) and test characteristics (using the cut-off with
the best ability to discriminate between occurrence and
nonoccurrence of grade 4 CIN) were sensitivity 73%,
specificity 74%, PPV 59%, and NPV 84%. Under tenfold
cross-validation conditions, the area under the ROC curve
was 0.78 (95% CI, 0.63–0.93), demonstrating that predic-
tive ability was only modestly decreased.
Risk factors for the occurrence of grade 4 CIN in the first
cycle of chemotherapy were also modeled by logistic
regression. Factors associated with a significant risk of or
protection against grade 4 CIN were broadly consistent
with the “any cycle” model with the exception of high
baseline bilirubin, low baseline white blood cell (WBC)
count, and age, which showed consistent direction of
effects, but only reached statistical significance in the
“any cycle” model. The area under the ROC curve for the
Table 2 Occurrence of grade 4 CIN by regimen type
Regimen groupa N b Any cycle grade 4 CIN, % (n) First cycle grade 4 CIN, % (n)
Total 444 34.4 (152) 24.4 (107)
Anthracycline-based 312 36.7 (114) 28.5 (88)
Sequential anthracycline-containing and taxane-containing 87 32.2 (28) 16.5 (14)
TAC 17 43.8 (7) 18.8 (3)
Other taxane-containing 10 22.2 (2) 22.2 (2)
CMF 18 5.6 (1) 0 (0)
CIN chemotherapy-induced neutropenia, CMF cyclophosphamide, methotrexate, and 5-fluorouracil, TAC Taxotere (docetaxel), Adriamycin
(doxorubicin), and cyclophosphamide
a Detailed information regarding treatment regimens has been reported elsewhere [8]
b Denominator values for calculations are the regimen N values in column 2, except as follows: any cycle grade 4 CIN: total (N=442), anthracycline-based
(N=311), TAC (N=16); first cycle grade 4 CIN: total (N=438), anthracycline-based (N=309), sequential anthracycline-containing and taxane-containing
(N=85), TAC (N=16), other taxane-containing (N=9) due to missing values
Table 3 Grade 4 CIN and impaired chemotherapy
Type of dose limitation Any grade 4 CIN Grade 4 CIN in cycle 1
Delaysa OR (95% CI) 1.57 (1.02–2.40) 1.23 (0.76–1.97)
Reductionsb, correctedc OR (95% CI) 1.86 (1.16–2.97) 1.64 (0.98–2.73)
RDI ≤85% OR (95% CI) 1.89 (1.15–3.10) 1.92 (1.13–3.26)
CIN chemotherapy-induced neutropenia, CI confidence interval, FN febrile neutropenia, OR odds ratio [italicized OR values indicate p<0.05],
RDI relative dose intensity
a In at least one cycle; ≥4 days
b In at least one antimalignant drug and at least one cycle; ≥10% of planned dose
c Taking into account nonadministered cycles
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“cycle 1” model was 0.73 (95% CI, 0.68–0.78). The PPV
was 38% and the NPV was 86%.
When the “any cycle” model was tentatively used to
predict CIN grades of 3 or higher, the area under the ROC
curve was 0.71 (95% CI, 0.66–0.76), and PPV and NPV
were 77% and 51%, respectively. Prediction for the first
cycle yielded an area under the ROC curve of 0.71 (95%
CI, 0.66–0.75). PPV was 62% and NPV was 64%. For CIN
grades of 2 or higher, ROC results were similar, but the
shift of predictive ability towards higher PPV and lower
NPV was stronger, given that 83% of patients experienced
this endpoint.
Patient scenarios
Table 5 shows the predicted risk of grade 4 CIN during any
cycle of chemotherapy for a selection of hypothetical
patients presenting various risk factors. Hypothetical sub-
jects of either 70 kg (the median weight of the breast cancer
study population) or 55 kg received chemotherapy with
either FEC followed by docetaxel (FEC-T) or TAC. This
table of predicted risk is based on the assumption that no
CSF support was given. Lower weight increased the risk of
grade 4 CIN at any age and for both types of chemotherapy
regimen, and the highest risk was in subjects with multiple
risk factors.
Discussion
In this sample of breast cancer patients receiving chemo-
therapy treatment, multivariate analyses were used to
identify risk factors for grade 4 CIN. Patient characteristics
contributing to increased risk were higher age and lower
Table 4 Logistic regression model for predicting occurrence of grade 4 CIN in any cycle of chemotherapy
Variable OR 95% CI p value
Age (per additional 10 years) 1.35 1.06 1.73 0.016
Weight (per additional 10 kg) 0.67 0.57 0.79 0.000
Planned doxorubicin dose intensitya 1.17 1.07 1.28 0.001
Planned epirubicin dose intensitya 1.14 1.08 1.19 0.000
Planned docetaxel dose intensitya 1.06 1.02 1.11 0.006
Planned number of cycles (per additional cycle) 1.65 1.27 2.14 0.000
Vascular comorbidity (present versus absent) 2.29 1.25 4.20 0.007
Baseline WBC count (×109/L) 0.87 0.76 0.99 0.037
Baseline bilirubin >17.1 µmol/L (1.0 mg/dl) 4.38 1.25 15.33 0.021
Baseline bilirubin missingb 2.62 0.78 8.78 0.118
Dose reductions before an event occurred (≥10% of planned dose) 0.21 0.05 0.99 0.049
Dose delays before an event occurred (≥4 days) 0.20 0.10 0.39 0.000
Cycle 1 nadir hematology lab unavailable 0.11 0.02 0.53 0.006
Hematology labs per cyclec 2.44 1.23 4.86 0.011
CSF before an event occurredd 0.36 0.18 0.70 0.003
Number of observations=434, Wald χ2 =160.69, p>χ2 <0.001, log pseudolikelihood=−209.49
CI confidence interval, CIN chemotherapy-induced neutropenia, CSF colony-stimulating factor, WBC white blood cell count
a Per additional milligram per square meter BSA per week
bMissing category introduced to avoid loss of observations
c Site-level average number of hematology laboratory tests per cycle (after cycle 1 and before a grade 4 CIN occurred; excluding start of cycle laboratory
tests)
dMyelopoietic growth factor use before a grade 4 CIN occurred
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Fig. 1 Scatter plot of absolute doxorubicin dose per kilogram body
weight in the first cycle of chemotherapy and BSA at baseline. AC
Adriamycin (doxorubicin) 60mg/m2 and cyclophosphamide 600 mg/m2,
TAC Taxotere (docetaxel) 75 mg/m2, doxorubicin 50 mg/m2, and
cyclophosphamide 500 mg/m2
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weight, vascular comorbidity and levels of some baseline
laboratory measures, specifically low baseline WBC count
and high baseline bilirubin. Treatment factors that increased
risk of grade 4 CIN were high planned chemotherapy dose
intensity, a higher number of planned chemotherapy cycles,
and a higher number of hematology laboratory tests measured
per cycle. CSF use, dose reductions, or dose delays, all before
a neutropenic event occurred, protected against grade 4 CIN.
The relationship between increased risk of myelotoxicity
and older age is well established and is incorporated in both
European and American clinical practice guidelines [10–12].
Lower weight may increase the risk of grade 4 CIN as a
result of drug dosing by BSA; as lighter patients are
exposed to more chemotherapy per kilogram of body
weight, this may result in higher toxicity. In our sample,
this assumption was supported by significant correlations
observed between dose per kilogram of each chemotherapy
agent and BSA.
In our model, a strong predictor for grade 4 CIN was
high baseline bilirubin, which is indicative of impaired liver
function [15]. Baseline bilirubin level may be a particularly
important predictive factor in patients receiving chemotherapy
with doxorubicin, epirubicin, or docetaxel, as these agents are
detoxified by the liver rather than excreted by the kidneys
[16]. Baseline laboratory measures of pretreatment ANC and
WBC count have been shown to predict neutropenic events
in breast cancer patients receiving FEC chemotherapy [17],
consistent with the present finding that low baseline WBC
was a risk factor for grade 4 CIN. From our dataset, we
could not confirm an independent role of lymphocyte count,
which has been reported by some authors [17–19].
High planned chemotherapy dose intensity of doxorubi-
cin, epirubicin, or docetaxel was a risk factor for grade 4
CIN. Using planned chemotherapy dose intensity as a
measure of the myelosuppressive potential of a regimen
allows comparison between different regimens and between
ranges of planned drug doses within the same regimen (for
example, in this study, epirubicin doses in FEC regimens
ranged from 50 to 120 mg/m2 BSA). As the model was
derived from data that reflect the “real-life” clinical
situation of dose variation, it can potentially be used in
clinical practice to predict grade 4 CIN in breast cancer
Table 5 Predicted risk of grade 4 CIN in any cycle of chemotherapy for breast cancer, in the absence of CSF support, according to age, weight,
and presence of risk factors
Risk factors Predicted risk (%)
55kga 70kga
35years 50years 65years 35years 50years 65years
FEC-T chemotherapyb
None 37 48 59 24 34 45
WBC lowc 46 58 68 32 43 54
Vascular comorbidity 57 68 77 43 54 65
Baseline bilirubin highd 72 80 86 59 69 78
WBC lowc + vascular comorbidity + bilirubin high 90 93 96 83 88 92
High number of hematology labs per cyclee 48 59 69 34 44 56
TAC chemotherapyf
None 61 71 80 46 58 68
WBC lowc 70 78 85 56 67 76
Vascular comorbidity 78 85 90 66 76 83
Baseline bilirubin highd 87 92 94 79 86 90
WBC lowc + vascular comorbidity + bilirubin high 96 97 98 93 95 97
High number of hematology labs per cyclee 71 79 86 57 68 77
BSA body surface area, CIN chemotherapy-induced neutropenia, CSF colony-stimulating factor, WBC white blood cell count
a The median weight of the breast cancer study population was 70 kg, and 55 kg was chosen to represent a low-weight patient. It was assumed that the cycle
1 nadir hematology laboratory test was available, that there were no dose delays or dose reductions before an event occurred, and that no CSF was
administered before an event occurred
b Standard FEC-T, i.e., three cycles of FEC with epirubicin 100 mg/m2 BSA followed by three cycles of docetaxel 100 mg/m2 BSA; cycle length 3 weeks
c Baseline WBC 4.0×109 /L instead of 6.7×109 /L
d Baseline bilirubin >17.1 µmol/L (1.0 mg/dl)
e 1.0 instead of 0.5 site-level average no. of hematology laboratory tests per cycle (after cycle 1 and before a grade 4CINoccurred; excluding start of cycle laboratory tests)
f Standard TAC, i.e., six cycles of TAC with doxorubicin 50 mg/m2 BSA and docetaxel 75 mg/m2 BSA; cycle length 3 weeks
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patients across a variety of regimens and doses. It should be
noted, however, that correlations with the use of other
antimalignant agents may have masked the contribution of
those agents to the neutropenic potential of the chemother-
apy regimens studied. Validation against an independent
dataset is pending.
The average number of hematology laboratory tests per
cycle at each study site (averaged across patients) and the
presence of a nadir hematology laboratory test in cycle 1
were significant predictive factors for grade 4 CIN. The most
probable explanation for this is that grade 4 CIN is more
likely to be detected at sites which tend to perform more
hematology laboratory tests. This observation raises the
possibility that neutropenic events may be underreported.
Consistent with current literature, CSF prophylaxis was
strongly protective against grade 4 CIN [10, 12, 20]. Dose
reductions and dose delays before an event occurred were also
identified as protective factors against grade 4 CIN; although
they may be an appropriate course of action to limit
neutropenia in patients receiving palliative treatment, in an
adjuvant setting, reductions in chemotherapy dose intensity
have been shown to impact negatively on treatment outcome
[2–5]. Current EORTC and American Society of Clinical
Oncology guidelines recommend CSF use to support dose
dense or dose intense regimens that have survival benefits
where reductions in intensity or density are known to be
associated with a poor prognosis or where a regimen ± risk
factors is associated with a >20% risk of FN [10, 12].
A recent model identified risk factors for FN or grade 4
CIN across multiple chemotherapy cycles in early stage
breast cancer patients in the US that were broadly similar to
those identified in our analysis [21]. The planned intensity
of different chemotherapy regimens impacted on the risk of
neutropenia in both models; in the US model, TAC
regimens were associated with the highest neutropenia risk,
consistent with the identification of planned dose intensity
of doxorubicin, epirubicin, or docetaxel as predictors in the
present model. Baseline bilirubin was a risk factor for
neutropenic events in both models, as was baseline WBC.
Lower glomerular filtration rate, predictive of neutropenic
events in the US model, was a replacement for age. CSF
use was protective against neutropenia in both analyses.
Risk and protective factors we identified for grade 4 CIN in
any cycle of chemotherapy were also identified in a model for
the first cycle of chemotherapy. Effect sizes were comparable,
although some covariates were no longer statistically signif-
icant, presumably due to the lower number of events in the
first cycle analysis. The only substantial reduction in effect
size was seen in baseline bilirubin. It is possible that, after one
cycle of chemotherapy, liver function was not sufficiently
impaired to affect chemotherapy drug metabolism, but with
repeated exposure to chemotherapy agents, this impairment
could have become more pronounced.
Our model showed good predictive ability, correctly
classifying 73% of grade 4 CIN patients and with an NPV
of 84%. Some predictive ability was maintained when the
endpoint was modified to include lower CIN grades. The
role of individual, intrinsic chemosensitivity, which we
cannot adequately predict to date, may make it difficult to
achieve better test characteristics in neutropenia risk models
[17]. The model performed well in tenfold cross-validation
but remains to be validated further against an independent
dataset.
To evaluate its potential clinical utility, the model was
applied to scenarios of hypothetical patients treated with
FEC-T, representative of a taxane–anthracycline sequential
therapy, which has been demonstrated to be efficacious in
the treatment of breast cancer [22], and TAC, representative
of a more myelotoxic regimen [10]. Older and lower weight
patients were shown to have a higher predicted risk of
grade 4 CIN, independent of other risk factors. The highest
risk of neutropenia was in patients with multiple risk
factors.
The identification of risk factors for grade 4 CIN has
important clinical implications. Current guidelines recom-
mend CSF use not only when the overall risk of FN is
>20%, but also to allow maintenance of chemotherapy
dose. Few patients in this dataset experienced FN; however,
grade 4 CIN was frequent and was associated with
chemotherapy dose delays, reductions, and low RDI. A
higher proportion of patients who had grade 4 CIN received
low RDI, compared to patients without grade 4 CIN. The
issue of impaired RDI achievement in routine practice
deserves greater attention. When the 20-year outcome
results from the Bonadonna study [3] are applied in
different breast cancer populations, the findings are similar;
namely, a lower than planned dose intensity is associated
with inferior long-term DFS and OS [23].
In conclusion, we have identified several risk factors for
grade 4 CIN in breast cancer patients receiving adjuvant
chemotherapy in the European practice. Our model pro-
vides a broad list of risk factors applicable across a range of
chemotherapy regimens. Such risk factors may be consid-
ered by clinicians identifying patients vulnerable to dose
reductions and delays, which may ultimately compromise
chemotherapy delivery, to enable appropriate targeting of
supportive care.
Acknowledgements The authors would like to thank the follow-
ing physicians for providing patient data: J.C.A. Adansa; J.J.C.
Hernandez; S. Al-Ismail; C. André; G.-A. Banat; A. Barnes; A.L.
Barriuso; J.L. Bello; A. Biswas; A. Bols; A. Brownell; W.
Brugger; R.O. Casasnovas; M. Clemens; R. Coleman; P. Colombat;
N. Davidson; R. Depenbusch; H.G. Derigs; A. Engert; J.C.
Espinosa; S. Ferrer; O. Fitoussi; B. Gaede; L. Garderet; B.
Hancock; M. Hänel; A. Hasenburg; A. Hong; U. Karck; G.
Köhler; A.W. Hutcheon; C. Lerchenmüller; R. Lipp; J.R.M.
Lorenzo; K. McAdam; F. Majois; J.L. Mansi; M.G. Martinez; J.
Support Care Cancer (2011) 19:483–490 489
Mebis; N. Mounier; A.A. Munoz; A. O’Callaghan; M. Quigley; S.
Rösel; C. Rudin; R. Schlag; G. Schlimok; M. Sandherr; P. Solal-
Celigny; T. Steck; H. Tesch; D. Turner; X. Vallantin; J. Van Erps;
E. Van Den Neste; A. Van Hoof; J.B. Vermorken; K. Verpoort; A.
Wardley; M. Warm; E. Weidmann; J. Wimperis; W. Zeller. The
authors wish to thank Prof. Gary Lyman, Duke University and the
Duke Comprehensive Cancer Center, Durham, North Carolina and
members of the Awareness of Neutropenia in Chemotherapy (ANC)
Study Group for the useful discussions comparing risk models. The
authors wish to thank Amgen (Europe) GmbH, Zug, Switzerland for
supporting this work with an educational grant. The authors wish to
thank medcept ltd., Switzerland, who provided medical writing
support to the INC-EU with funding from Amgen (Europe) GmbH.
Conflicts of interest This study was supported by an educational
grant from Amgen (Europe) GmbH. M.S. receives research funding
from Amgen and acts as a consultant in receipt of honoraria from
Amgen. R.P. is a consultant in receipt of honoraria from Chugai,
Bayer, Roche, and Amgen. C.J. is a consultant in receipt of honoraria
from Amgen and Astra Zeneca. R.Pa. is a consultant in receipt of
honoraria from Astra Zeneca, Novartis, Pfizer, Sanofis, and Schering-
Plough and receives research funding from Amgen, Novartis, and
Pfizer. M.C. has no conflicts of interest to declare. A.B. receives
research funding from Amgen. T.S. has no conflicts of interest to
declare. R.L. has modest share ownership interest in GlaxoSmithKline,
is a consultant in receipt of honoraria from Amgen, Astra Zeneca,
Novartis, Pfizer, Roche, and Zeneus, and was in receipt of research
funding from Amgen.
References
1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P
(2007) Estimates of the cancer incidence and mortality in Europe
in 2006. Ann Oncol 18(3):581–592
2. Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S,
Gianni L, Valagussa P (2005) 30 years' follow up of randomised
studies of adjuvant CMF in operable breast cancer: cohort study.
Br Med J 330(7485):217
3. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C
(1995) Adjuvant cyclophosphamide, methotrexate, and fluoroura-
cil in node-positive breast cancer: the results of 20 years of
follow-up. N Engl J Med 332(14):901–906
4. Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood
WC, Weiss RB, Ferree CR, Muss HB, Green MR, Norton L, Frei
E 3rd (1998) Dose and dose intensity as determinants of outcome
in the adjuvant treatment of breast cancer. The Cancer and
Leukemia Group B. J Natl Cancer Inst 90(16):1205–1211
5. Chirivella I, Bermejo B, Insa A, Perez-Fidalgo A, Magro A,
Rosello S, Garcia-Garre E, Martin P, Bosch A, Lluch A (2009)
Optimal delivery of anthracycline-based chemotherapy in the
adjuvant setting improves outcome of breast cancer patients.
Breast Cancer Res Treat 114(3):479–484
6. von Minckwitz G, Schwenkglenks M, Skacel T, Lyman G, Lopez-
Pousa A, Bacon P, Easton V, Aapro M (2009) Febrile neutropenia
and related complications in breast cancer patients receiving
pegfilgrastim primary prophylaxis versus current practice neutro-
penia management: results from an integrated analysis. Eur J
Cancer 45(4):608–617
7. Leonard RC, Miles D, Thomas R, Nussey F (2003) Impact of
neutropenia on delivering planned adjuvant chemotherapy: UK audit
of primary breast cancer patients. Br J Cancer 89(11):2062–2068
8. Pettengell R, Schwenkglenks M, Leonard R, Bosly A, Paridaens
R, Constenla M, Szucs TD, Jackisch C (2008) Neutropenia
occurrence and predictors of reduced chemotherapy delivery:
results from the INC-EU prospective observational European
neutropenia study. Support Care Cancer 16(11):1299–1309
9. Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of
primary prophylaxis with granulocyte colony-stimulating factor
on febrile neutropenia and mortality in adult cancer patients
receiving chemotherapy: a systematic review. J Clin Oncol 25
(21):3158–3167
10. Aapro MS, Cameron DA, Pettengell R, Bohlius J, Crawford J,
Ellis M, Kearney N, Lyman GH, Tjan-Heijnen VC, Walewski J,
Weber DC, Zielinski C (2006) EORTC guidelines for the use of
granulocyte-colony stimulating factor to reduce the incidence of
chemotherapy-induced febrile neutropenia in adult patients with
lymphomas and solid tumours. Eur J Cancer 42(15):2433–2453
11. National Comprehensive Cancer Network Inc. (2008) NCCN
clinical practice guidelines in oncology—breast cancer V.2.2008.
Available at http://www.nccn.org/professionals/physician_gls/
PDF/breast.pdf. Accessed on 5 December 2008
12. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO,
Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ,
Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L,
Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak
AJ, Wolff AC (2006) 2006 update of recommendations for the use
of white blood cell growth factors: an evidence-based clinical
practice guideline. J Clin Oncol 24(19):3187–3205
13. Greenland S, Finkle WD (1995) A critical look at methods for
handling missing covariates in epidemiologic regression analyses.
Am J Epidemiol 142(12):1255–1264
14. Vach W, Blettner M (1991) Biased estimation of the odds ratio in
case–control studies due to the use of ad hoc methods of
correcting for missing values for confounding variables. Am J
Epidemiol 134(8):895–907
15. Field KM, Dow C, Michael M (2008) Part I: liver function in
oncology: biochemistry and beyond. Lancet Oncol 9(11):1092–1101
16. Hladnik M, Wills AR, Augustin KM (2007) Systemic chemother-
apy: special considerations. In: The Washington manual of
oncology, 2nd ed. Lippincott Williams and Wilkins, pp 30–32
17. Jenkins P, Freeman S (2009) Pretreatment haematological labora-
tory values predict for excessive myelosuppression in patients
receiving adjuvant FEC chemotherapy for breast cancer. Ann
Oncol 20:34–40
18. Blay JY, Chauvin F, Le Cesne A, Anglaret B, Bouhour D, Lasset
C, Freyer G, Philip T, Biron P (1996) Early lymphopenia after
cytotoxic chemotherapy as a risk factor for febrile neutropenia. J
Clin Oncol 14(2):636–643
19. Borg C, Ray-Coquard I, Philip I, Clapisson G, Bendriss-Vermare
N, Menetrier-Caux C, Sebban C, Biron P, Blay JY (2004) CD4
lymphopenia as a risk factor for febrile neutropenia and early
death after cytotoxic chemotherapy in adult patients with cancer.
Cancer 101(11):2675–2680
20. Komrokji RS, Lyman GH (2004) The colony-stimulating factors:
use to prevent and treat neutropenia and its complications. Exp
Hematol 4(12):1897–1910
21. Culakova E, Wolff DA, Poniewierksi MS, Crawford J, Dale DC,
Lyman GH (2008) Factors related to neutropenic events in early
stage breast cancer patients. J Clin Oncol 26(Suppl):Abstract 634
22. Roche H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin
D, Symann M, Kerbrat P, Soulie P, Eichler F, Viens P, Monnier A,
Vindevoghel A, Campone M, Goudier MJ, Bonneterre J, Ferrero
JM, Martin AL, Geneve J, Asselain B (2006) Sequential adjuvant
epirubicin-based and docetaxel chemotherapy for node-positive
breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol
24(36):5664–5671
23. Kahlert S, Rosenfeld J, Mair K, Sorokina Y, Engel J, and Friese K
(2008) Adjuvant chemotherapy for breast cancer prognostic
impact of relative dose–intensity. 31st Annual San Antonio Breast
Cancer Symposium (SABCS), Abstract 4109
490 Support Care Cancer (2011) 19:483–490
